Pathophysiology of the antiphospholipid syndrome (APS)

Revue de Medecine Interne

Volumn 33, Issue SUPPL. 2, 2012, Pages

  Meroni, P L ^a,b   Chighizola, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; PHOSPHATIDYLSERINE;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOTHELIUM; FETUS DEATH; HUMAN; INFLAMMATION; MONOCYTE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE; VASCULAR DISEASE; VEIN THROMBOSIS;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84870236559     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.09.010     Document Type: Article

References (20)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Meroni P.L., Borghi M., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
3. Shoenfeld Y., Meroni P.L., Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Curr Opin Rheumatol 2009, 21:495-500.
4. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipidsyndrome. Lancet 2010, 376:1498-1509.
5. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
6. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
7. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management inantiphospholipid syndrome. Autoimmun Rev 2012, [Epub ahead of print].
8. Andreoli L., Nalli C., Motta M., Norman G.L., Shums Z., Encabo S., et al. Anti-beta-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Ann Rheum Dis 2011, 70:380-383.
9. Nalli C, Andreoli L, Norman GL, Shums Z, Binder W, Encabo S et al. Antibodies versus Domain I of B2GPI as a marker of systemic autoimmunity. Abstract, 8th International Congress on Autoimmunity, Granada, Spain. 2012.
10. Agar C., van Os G.M., Mörgelin M., Sprenger R.R., Marquart J.A., Urbanus R.T., et al. β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2006, 116:1336-1343.
11. Bertolaccini M.L. Antibodies to prothrombin. Lupus 2012, 21(7):729-731.
12. Tincani A., Spatola L., Prati E., Allegri F., Ferremi P., Cattaneo R., et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996, 157:5732-5738.
13. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010, 19:460-469.
14. Meroni P.L., Tedesco F., Locati M., Vecchi A., Di Simone N., Acaia B., et al. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus 2010, 19:453-456.
15. Martinez de la Torre Y., Buracchi C., Borroni E.M., Dupor J., Bonecchi R., Nebuloni M., et al. Protection against inflammation - and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007, 104:2319-2324.
16. de la Torre Y.M., Pregnolato F., D'Amelio F., Grossi C., Di Simone N., Pasqualini F., et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 2012, 38:J209-J215.
17. Tincani A., Rebaioli C.B., Andreoli L., Lojacono A., Motta M. Neonataleffects of maternalantiphospholipid syndrome. Curr Rheumatol Rep 2009, 11:70-76.
18. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., Meroni P. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006, 65:2-6.
19. Agostinis C., Biffi S., Garrovo C., Durigutto P., Lorenzon A., Bek A., et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 2011, 118:4231-4238.
20. Meroni P.L., Raschi E., Grossi C., Pregnolato F., Trespidi L., Acaia B., et al. Obstetric and vascular APS: sameautoantibodies but differentdiseases?. Lupus 2012, 21:708-710.